| Literature DB >> 32714402 |
Zaofeng Zou1,2,3, Jingxian Sun1,2, Zheng Kang1,2, Yumeng Wang1,2, Hui Zhao1,2,4,5, Keying Zhu1,2,6, Jun Wang1,2,4,5.
Abstract
Electroacupuncture has been shown to promote remyelination in a demyelinating model of multiple sclerosis (MS) through enhanced microglial clearance of degraded myelin debris. However, the mechanisms involved in this process are yet to be clearly elucidated. It has been revealed that TAM receptor tyrosine kinases (Tyro3, Axl, and MerTK) play pivotal roles in regulating multiple features of microglia, including the phagocytic function and myelin clearance. Therefore, the aim of this study is to further confirm whether electroacupuncture improves functional recovery in this model and to characterise the involvement of the TAM receptor during this process. In addition to naive control mice, a cuprizone-induced demyelinating model was established, and long-term electroacupuncture treatment was administrated. To evaluate the efficiency of functional recovery following demyelination, we performed beam-walking test and rotarod performance test; to objectify the degree of remyelination, we performed transmission electron microscopy and protein quantification of mature oligodendrocyte markers. Oil Red O staining was used to evaluate the deposit of myelin debris. We confirmed that, in cuprizone-treated mice, electroacupuncture significantly ameliorates motor-coordinative dysfunction and counteracts demyelinating processes, with less deposit of myelin debris accumulating in the corpus callosum. Surprisingly, mRNA expression of TAM receptors was significantly upregulated after electroacupuncture treatment, and we further confirmed an increased protein expression of Axl and MerTK after electroacupuncture treatment, indicating their involvement during electroacupuncture treatment. Finally, LDC1267, a selective TAM kinase inhibitor, abolished the therapeutic effect of electroacupuncture on motor-coordinative dysfunction. Overall, our data demonstrate that electroacupuncture could mitigate the progression of demyelination by enhancing the TAM receptor expression to facilitate the clearance of myelin debris. Our results also suggest that electroacupuncture may be a potential curative treatment for MS patients.Entities:
Year: 2020 PMID: 32714402 PMCID: PMC7355344 DOI: 10.1155/2020/3205176
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1EA ameliorates motor-coordinative dysfunction associated to CPZ administration. (a) The scheme of experiment: CPZ administration is withdrawn after 5 weeks (demyelination phase) followed by 1 week of the remyelination phase. Mice received 3 weeks of EA treatment since the 1st day at week 4 when they started exhibiting severe defects in neurological behaviours. Behavioral test is performed at the end of weeks 5 and 6. (b) The location of Baihui (GV20) and Zhiyang (GV9) acupoints. (c and d) EA treatment significantly reduces the time spent in beam-walking test at week 5. EA treatment significantly increases the time remaining on the cylinder at week 5. All data are represented as means ± SEM (n = 6–8 for each group; p < 0.05, p < 0.01).
Primers used for RT-PCR analysis.
| Genes | Species | Sequence (5′-greater than 3′) |
|---|---|---|
|
| Mouse | FW: CAGGGCCTTTACCAGGGAGA |
| RE: TGTGTGCTGGATGTGATCTTC | ||
|
| Mouse | FW: ATGGCCGACATTGCCAGTG |
| RE: CGGTAGTAATCCCCGTTGTAGA | ||
|
| Mouse | FW: GCCTCCAAATTGCCCGTCA |
| RE: CCAGCACTGGTACATGAGATCA | ||
|
| Mouse | FW: GGGCCTAAAACTATCCCCAGA |
| RE: GGTACAAGGACTTCACGCTCT | ||
|
| Mouse | FW: GGTTGTCTCCTGCGACTTCA |
| RE: TGGTCCAGGGTTTCTTACTCC |
Figure 2EA treatment reduces CPZ-induced demyelination. (a) The protein expression of MBP in each group at weeks 5 and 6. EA treatment significantly increases the expression of myelin-related protein. (b) Bar graph shows the quantification of the MBP expression by western blot (n = 5 for each group). Consistently, (c) immunostaining of MBP shows the effect of promoting remyelination by EA treatment (scale bar = 50 μm). (d and e) Ultrastructure of axon/myelin by TEM. EA treatment significantly increases the percentage of the myelinated axon per image field (scale bar = 2 μm) and decreases the number of swollen axons (black arrows). (f) Scatter plot of individual g-ratio against axonal perimeter (left panel) and the integrated g-ratio values among groups (right panel). All data are represented as means ± SEM (p < 0.05, p < 0.01, and p < 0.001).
Figure 3EA promotes the clearance of degraded myelin debris. (a) Oil Red O staining shows that the lipid-associated deposit of degraded myelin debris is eliminated after 2 weeks of EA treatment. (b) Microglia assembling into the corpus callosum at weeks 5 and 6 is detected by Iba1 (green), and representative microglia displaying the amoeboid and phagocytic shape after EA treatment with higher magnification (scale bar = 20 μm). All data are represented as means ± SEM (for statistical graph: n = 5 for each group; p < 0.05, p < 0.01, and p < 0.001).
Figure 4EA increases the mRNA expression of phagocytosis-related receptors MerTK and Axl in the corpus callosum. (a–d) mRNA level of genes of the TAM receptor family in each group at weeks 5 and 6 (n = 4–8 for each group; all data are represented as means ± SEM p < 0.05; p < 0.01).
Figure 5EA upregulates the expression of MerTK in the corpus callosum. Immunofluorescence staining of MerTK (red), Iba1 (green), and merge (scale bar = 20 μm). All data are represented as means ± SEM (for statistical graph: n = 4–6 for each group; p < 0.05, p < 0.01, and p < 0.001).
Figure 6EA upregulates the expression of Axl in the corpus callosum. Immunofluorescence staining of Axl (red), Iba1 (green), and merge (scale bar = 20 μm). All data are represented as means ± SEM (for statistical graph: n = 4-5 for each group; p < 0.05, p < 0.01, and p < 0.001).
Figure 7TAM kinase inhibitor LDC1267 abolishes the therapeutic effect of EA on motor dysfunction. EA treatment significantly reduces the time spent in beam-walking test and increases the time remaining on the cylinder at week 5. LDC1267 eliminates the effects of EA treatment. All data are represented as means ± SEM (n = 6–8 for each group; p < 0.05, p < 0.01, and p < 0.001).